Revolution Medicines (RVMD) Income from Continuing Operations (2019 - 2026)
Revolution Medicines (RVMD) recorded quarterly Income from Continuing Operations of 453816000.0 in Q1 2026, down 159.21% quarter-over-quarter from 766409000.0 in Q4 2025, and down 112.64% on a YoY basis from 3589223075.01 in Q1 2025.
Revolution Medicines (RVMD) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Revolution Medicines' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 453816000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 112.64% year-over-year to 453816000.0; the TTM figure through Mar 2026 stood at 240400000.0 (up 65.53% YoY), while the FY2024 annual figure was 600043000.0, down 36.31% from the prior year.
- Income from Continuing Operations was 453816000.0 for Q1 2026 at Revolution Medicines, down from 766409000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 766409000.0 in Q4 2025 to a low of 453816000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 102517588.24 across 5 years, with a median of 116003000.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations plunged 192.58% in 2023, then jumped 494.0% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 56527000.0 in 2022, then sank by 192.58% to 165385000.0 in 2023, then dropped by 17.62% to 194519000.0 in 2024, then surged by 494.0% to 766409000.0 in 2025, then tumbled by 159.21% to 453816000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 453816000.0 (Q1 2026), 766409000.0 (Q4 2025), and 305206000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Revolution Medicines | 32.33 Bn | 32.33 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -453.82 Mn |
| Dec 31, 2025 | 766.41 Mn |
| Sep 30, 2025 | -305.21 Mn |
| Jun 30, 2025 | -247.79 Mn |
| Mar 31, 2025 | -213.42 Mn |
| Dec 31, 2024 | -194.52 Mn |
| Sep 30, 2024 | -156.29 Mn |
| Jun 30, 2024 | -133.23 Mn |
| Mar 31, 2024 | -116.00 Mn |
| Dec 31, 2023 | -165.39 Mn |
| Sep 30, 2023 | -108.43 Mn |
| Jun 30, 2023 | -98.30 Mn |
| Mar 31, 2023 | -68.10 Mn |
| Dec 31, 2022 | -56.53 Mn |
| Sep 30, 2022 | -73.33 Mn |
| Jun 30, 2022 | -61.22 Mn |
| Mar 31, 2022 | -57.65 Mn |
| Dec 31, 2021 | -52.68 Mn |
| Sep 30, 2021 | -52.94 Mn |
| Jun 30, 2021 | -44.30 Mn |